IPP Bureau
Manipal Hospitals deploys wearable technology to monitor post-surgery care
By IPP Bureau - March 19, 2022
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
USFDA approves Opdualag to treat metastatic melanoma
By IPP Bureau - March 19, 2022
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Tata Elxsi has unveiled TEngage, a digital health platform
By IPP Bureau - March 19, 2022
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
USFDA approves Marinus’ treatment for genetic disorder
By IPP Bureau - March 19, 2022
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Aesculap launches new sterile container system
By IPP Bureau - March 19, 2022
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
.jpg "Thirty five generic manufacturers sign agreements with MPP for Paxlovid")
Thirty five generic manufacturers sign agreements with MPP for Paxlovid
By IPP Bureau - March 18, 2022
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
AstraZeneca launches global R&D post-doctoral challenge
By IPP Bureau - March 18, 2022
Successful proposals will secure fully funded postdoctoral research positions
Merck discontinues KEYLYNK-101 trial to treat prostate cancer
By IPP Bureau - March 18, 2022
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Health Canada authorizes Moderna's COVID-19 vaccine in children (6-11 Years)
By IPP Bureau - March 18, 2022
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
11-year-old Oman girl undergoes gastro trichobezoar surgery
By IPP Bureau - March 18, 2022
Doctors at Yashoda Hospitals Hyderabad perform rare operation
Sanofi moves forward with EUROAPI listing on Euronext Paris
By IPP Bureau - March 18, 2022
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Flipkart Health+ appoints Prashant Jhaveri as CEO
By IPP Bureau - March 17, 2022
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
Community approach crucial to stamp out diseases
By IPP Bureau - March 17, 2022
The Karnataka Health Promotion Trust held a day-long session in New Delhi to address health care challenges
Roche introduces molecular testing solutions to differentiate Covid-19 variants
By IPP Bureau - March 17, 2022
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
BASF to double production capacity of dispersion at its site in Indonesia
By IPP Bureau - March 17, 2022
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
